OralTopicalDosed ingredientTherapeutic flag Cosmetic cross-reference

Minoxidil

CAS 38304-91-5

Minoxidil (CAS 38304-91-5) is a Phase 4 pharmaceutical compound with 2 bioactivity targets and 1,252 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
5
SOURCE DrugCentral
Adverse signals
1,252
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Minoxidil
CAS Number
38304-91-5
UNII
5965120SH1
InChIKey
ZFMITUMMTDLWHR-UHFFFAOYSA-N
ChEMBL ID
CHEMBL802
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
Rogaine
black box warningdosed ingredientnatural productoraltherapeutic flagtopical
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL802 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE EMBL-EBI ChEMBL 5 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- AC50 22219.246857142858 nM 70 -
- Potency 14693.24705882353 nM 17 -
- IC50 20820.655 nM 3 -
ATP-sensitive inward rectifier potassium channel 1
Ion channel
 IC50 6.97 - Homo sapiens
Sulfonylurea receptor 2, Kir6.2
Ion channel
 OPENER - - Homo sapiens
SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Hypertrichosis 117 634.874 10020864
Product formulation issue 83 441.233 10069228
Pericardial effusion 98 184.259 10034474
Hair texture abnormal 23 66.387 10019049
Application site pruritus 22 58.231 10003053
Hair growth abnormal 20 57.599 10019044
Nephrogenic systemic fibrosis 24 55.464 10067467
Dermatitis contact 28 54.441 10012442
Renal cyst haemorrhage 13 53.043 10059846
Product monitoring error 22 48.367 10081575
Hypertensive crisis 31 48.194 10020802
Cardiac failure congestive 74 47.99 10007559
Product label on wrong product 8 46.332 10069268
Hair colour changes 18 45.446 10019030
Application site pain 19 44.573 10003051
Application site exfoliation 11 43.587 10064578
Vascular anastomotic haemorrhage 9 41.721 10084092
Ceruloplasmin increased 6 41.536 10008219
Renal artery stenosis 16 41.328 10038378
Hypertension 120 41.003 10020772
Intraductal papillary mucinous neoplasm 11 40.525 10070999
Left ventricular hypertrophy 22 38.893 10049773
Cardiac tamponade 20 38.621 10007610
Injection site alopecia 6 38.419 10081519
Oedema peripheral 94 37.95 10030124
Scrotal oedema 12 37.346 10039755
Perineal cyst 8 36.522 10066058
Blood copper increased 6 36.495 10005443
Erectile dysfunction 24 35.711 10061461
Vena cava injury 8 34.678 10047194
Hypotension 125 34.635 10021097
Aortic dilatation 12 33.777 10057453
Oliguria 22 33.762 10030302
Rectal prolapse 12 33.632 10038077
Delayed graft function 13 33.533 10076664
Vascular compression 9 33.414 10070995
Abdominal wall haemorrhage 9 33.264 10067788
Tachycardia 70 33.117 10043071
Skin induration 14 31.319 10051837
Carotid arteriosclerosis 12 31.26 10067116
Cardiac hypertrophy 11 31.239 10007572
Hypervolaemia 31 30.498 10020919
Complications of transplanted kidney 15 30.354 10010185
Swelling of eyelid 13 29.78 10042690
Hyperparathyroidism secondary 12 29.669 10020708
Application site reaction 9 28.207 10003055
Palpitations 55 27.862 10033557
Product administration error 28 27.853 10081576
Blood 25-hydroxycholecalciferol decreased 7 27.084 10053813
Actinic keratosis 14 26.77 10000614

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR/BPS 2 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

TargetAction AffinityPubMed
K ir 6.1
KCNJ8
 Activator - -
K ir 6.2
KCNJ11
 Activator - -
SOURCE NLM RxNorm 5 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
Minoxidil 6984 SU MTHSPL
minoxidil 6984 SU MTHSPL
MINOXIDIL 6984 SU MTHSPL
minoxidil 6984 IN RXNORM
Rogaine 225702 BN RXNORM
SOURCE SIDER 75 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side EffectDrug Name MedDRA TypeConcept ID
Angina pectoris minoxidil LLT C0002962
Angina pectoris minoxidil PT C0002962
Blood alkaline phosphatase increased minoxidil PT C0852911
Blood and lymphatic system disorders minoxidil - C0851353
Blood creatinine increased minoxidil PT C0235431
Breast disorder minoxidil LLT C0006145
Breast disorder minoxidil PT C0006145
Breast tenderness minoxidil LLT C0262397
Breast tenderness minoxidil PT C0262397
Bullous eruption minoxidil LLT C0235818
Cardiac disorder minoxidil LLT C0018799
Cardiac disorder minoxidil PT C0018799
Cardiac tamponade minoxidil LLT C0007177
Cardiac tamponade minoxidil PT C0007177
Dermatitis minoxidil PT C0011603
Dermatitis bullous minoxidil LLT C0085932
Dermatitis bullous minoxidil PT C0085932
Dermatitis bullous minoxidil PT C0085932
Electrocardiogram ST segment minoxidil LLT C0429029
Electrocardiogram ST segment minoxidil PT C0429029
Electrocardiogram abnormal minoxidil LLT C0522055
Electrocardiogram abnormal minoxidil PT C0522055
Erythema multiforme minoxidil PT C0014742
Fluid retention minoxidil LLT C0268000
Fluid retention minoxidil PT C0268000
Fluid retention minoxidil PT C0268000
Gastrointestinal disorder minoxidil LLT C0017178
Gastrointestinal disorder minoxidil PT C0017178
Hair colour changes minoxidil LLT C0474378
Hair colour changes minoxidil PT C0474378
Hair growth abnormal minoxidil LLT C0232409
Hair growth abnormal minoxidil PT C0232409
Hypertrichosis minoxidil LLT C0020555
Hypertrichosis minoxidil PT C0020555
Hypotension minoxidil LLT C0020649
Hypotension minoxidil PT C0020649
Leukopenia minoxidil LLT C0023530
Leukopenia minoxidil PT C0023530
Malnutrition minoxidil LLT C0162429
Malnutrition minoxidil PT C0162429
Mediastinal disorder minoxidil LLT C0025061
Mediastinal disorder minoxidil PT C0025061
Nausea minoxidil LLT C0027497
Nausea minoxidil PT C0027497
Oedema minoxidil LLT C0013604
Oedema minoxidil PT C0013604
Oedema peripheral minoxidil LLT C0085649
Oedema peripheral minoxidil PT C0085649
Pericardial effusion minoxidil LLT C0031039
Pericardial effusion minoxidil PT C0031039
Pericarditis minoxidil LLT C0031046
Pericarditis minoxidil PT C0031046
Phosphatase alkaline increased minoxidil LLT C0151849
Pleural effusion minoxidil LLT C0032227
Pleural effusion minoxidil PT C0032227
Rash minoxidil LLT C0015230
Rash minoxidil PT C0015230
Serum creatinine increased minoxidil LLT C0700225
Skin disorder minoxidil PT C0037274
Stevens-Johnson syndrome minoxidil LLT C0038325
Stevens-Johnson syndrome minoxidil PT C0038325
Tachycardia minoxidil LLT C0039231
Tachycardia minoxidil PT C0039231
Thrombocytopenia minoxidil LLT C0040034
Thrombocytopenia minoxidil PT C0040034
Toxic epidermal necrolysis minoxidil LLT C0014518
Toxic epidermal necrolysis minoxidil PT C0014518
Unspecified disorder of skin and subcutaneous tissue minoxidil LLT C0178298
Virilism minoxidil LLT C0042755
Virilism minoxidil PT C0042755
Vomiting minoxidil LLT C0042963
Vomiting minoxidil PT C0042963
Water retention minoxidil LLT C0542203
Weight increased minoxidil LLT C0043094
Weight increased minoxidil PT C0043094
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Minoxidil used for in pharmaceutical contexts?

Minoxidil (CAS 38304-91-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Minoxidil?

Minoxidil has 1,252 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Hypertrichosis, Product formulation issue, Pericardial effusion, Hair texture abnormal, Application site pruritus. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Minoxidil also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Minoxidil with EU status "prohibited".

What clinical phase is Minoxidil in?

Minoxidil is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Minoxidil?

Minoxidil has 5 bioactivity rows in this page query. Rendered target entries include ATP-sensitive inward rectifier potassium channel 1, Sulfonylurea receptor 2, Kir6.2.